“Biomaterials Market Report is set to have rapid growth due growing industrialization in both developed and developing nations, strong government support, suitable strategic framework, and continuous R&D at global, regional and national level, influencing the industry trends in each of the sub-segments from 2019 to 2029”, says Visiongain Report

04 September 2019
Pharma

Visiongain has launched a new pharma report Biomaterials Market Forecast 2019-2029: By Product (Natural, Metallic, Ceramics, Polymers), By Application (Cardiovascular, Orthopedics, Plastic Surgery), Regional and Segment Forecasts

The global Biomaterials market is poised for rapid growth between 2019 and 2029. Factors such as increased funds and subsidies from government agencies around the world for the development of new biomaterials, the growing demand for medical implants and the growing incidence of cardiovascular disease are driving the growth of the biomaterials market.

Technological innovations in the field of biomaterials are leading to the development of advanced products, which in turn is working in favor of the market. The expansion of the geriatric population base worldwide and the consequent increase in the prevalence of cardiovascular and orthopedic disorders are providing a problem to the market.

Biomaterials are now widely used in health care sectors such as cardiovascular, orthopedic, dental, plastic, wound repair, ophthalmology and neurological conditions. Furthermore, they are used in various advanced health technologies such as cosmetic surgery, tissue engineering, medical implants and advanced drug delivery.

Leading companies featured in the report include DSM; BASF SE; Evonik Industries AG.; Berkeley Advanced Biomaterials, Inc.; CAM Bioceramics BV; Carpenter Technology Corporation; Invibio Ltd.; Zimmer Biomet Holdings, Inc.; Covalon Technologies Ltd.; Collagen Matrix, Inc.; Medtronic, Inc.; Purac Biomaterials; Ticona GmbH; Osteotech, Inc.; and Bayer AG.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever